76 related articles for article (PubMed ID: 16358262)
1. Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice.
Rustamzadeh E; Hall WA; Todhunter DA; Low WC; Liu H; Panoskaltsis-Mortari A; Vallera DA
Int J Cancer; 2006 May; 118(10):2594-601. PubMed ID: 16358262
[TBL] [Abstract][Full Text] [Related]
2. Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13.
Rustamzadeh E; Vallera DA; Todhunter DA; Low WC; Panoskaltsis-Mortari A; Hall WA
J Neurooncol; 2006 May; 77(3):257-66. PubMed ID: 16314943
[TBL] [Abstract][Full Text] [Related]
3. Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice.
Rustamzadeh E; Hall WA; Todhunter DA; Vallera VD; Low WC; Liu H; Panoskaltsis-Mortari A; Vallera DA
Int J Cancer; 2007 Jan; 120(2):411-9. PubMed ID: 17075792
[TBL] [Abstract][Full Text] [Related]
4. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
Li C; Hall WA; Jin N; Todhunter DA; Panoskaltsis-Mortari A; Vallera DA
Protein Eng; 2002 May; 15(5):419-27. PubMed ID: 12034862
[TBL] [Abstract][Full Text] [Related]
5. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.
Liu TF; Hall PD; Cohen KA; Willingham MC; Cai J; Thorburn A; Frankel AE
Clin Cancer Res; 2005 Jan; 11(1):329-34. PubMed ID: 15671563
[TBL] [Abstract][Full Text] [Related]
6. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
7. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Rustamzadeh E; Li C; Doumbia S; Hall WA; Vallera DA
J Neurooncol; 2003 Oct; 65(1):63-75. PubMed ID: 14649886
[TBL] [Abstract][Full Text] [Related]
8. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model.
Stish BJ; Oh S; Vallera DA
J Neurooncol; 2008 Mar; 87(1):51-61. PubMed ID: 18084721
[TBL] [Abstract][Full Text] [Related]
9. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
[TBL] [Abstract][Full Text] [Related]
10. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.
Oh S; Ohlfest JR; Todhunter DA; Vallera VD; Hall WA; Chen H; Vallera DA
J Neurooncol; 2009 Dec; 95(3):331-342. PubMed ID: 19517064
[TBL] [Abstract][Full Text] [Related]
11. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
Vallera DA; Li C; Jin N; Panoskaltsis-Mortari A; Hall WA
J Natl Cancer Inst; 2002 Apr; 94(8):597-606. PubMed ID: 11959893
[TBL] [Abstract][Full Text] [Related]
12. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
[TBL] [Abstract][Full Text] [Related]
13. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 Nov; 13(21):6486-93. PubMed ID: 17975161
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
Avramis IA; Christodoulopoulos G; Suzuki A; Laug WE; Gonzalez-Gomez I; McNamara G; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2002 Dec; 50(6):479-89. PubMed ID: 12451475
[TBL] [Abstract][Full Text] [Related]
15. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107.
Hagihara N; Walbridge S; Olson AW; Oldfield EH; Youle RJ
Cancer Res; 2000 Jan; 60(2):230-4. PubMed ID: 10667564
[TBL] [Abstract][Full Text] [Related]
16. In vitro efficacy of recombinant diphtheria toxin-murine interleukin-4 immunoconjugate on mouse glioblastoma and neuroblastoma cell lines and the additive effect of radiation.
Kim KU; Vallera DA; Ni HT; Cho KH; Low WC; Hall WA
Neurosurg Focus; 2000 Dec; 9(6):e5. PubMed ID: 16817688
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo intracellular distribution and anti-glioblastoma effects of docetaxel-loaded nanoparticles functioned with IL-13 peptide.
Gao H; Zhang S; Yang Z; Cao S; Jiang X; Pang Z
Int J Pharm; 2014 May; 466(1-2):8-17. PubMed ID: 24607217
[TBL] [Abstract][Full Text] [Related]
18. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
19. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture.
Liu TF; Cohen KA; Willingham MC; Tatter SB; Puri RK; Frankel AE
J Neurooncol; 2003 Oct; 65(1):77-85. PubMed ID: 14649887
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]